Just realized, I celebrate my 15th Twitterversary this month. Back then, I never imagined this app would become a second home. What started as a place to share ideas has grown into so much more. This platform has allowed me to share biotech insights, bounce ideas, and learn

Lots of failed studies end up stat sig when you selectively exclude patients. Lol

🛒 Shopping online? Don’t let weak passwords ruin your holiday. Avoid using personal info like names or birthdays. Create strong, unique passwords for each account and turn on multifactor authentication. Learn more and download free resources!

$PVLA Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel for the Treatment of Angiokeratomas

$NKTR primary endpoint narrowly missed statistical significance with the mean percent SALT reduction at Week 36 of 28.2% for the 24 µg/kg rezpegaldesleukin arm, 30.3% for the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively)

$NKTR data from the patients ongoing in the 16-week treatment extension will be available in early Q2

Did you know that asphalt is recycled? Here's how.

$NKTR achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms versus 6% for placebo,

$NKTR REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata https://t.co/A20HrV2aRJ

$NKTR halt

$ADAG Announces FDA Fast Track Designation for Muzastotug (ADG126)

Experience comfortable reading with lenses designed to reduce blue-light exposure and enhance visual clarity. The dual-focus design supports both near and mid-distance viewing, helping you read and work with ease throughout the day.

The Home column on @Pro is all messed up, showing totally irrelevant and random posts. Fit it @X 🤦‍♂️

$ABVX PT raised to $131 Citizens JMP

$TYRA added to Best Ideas List at Wedbush. PT raised to $37

$CLYM Ra capital 314.5k at 2.4, total $754k worth

$ALDX PDUFA extended for Reproxalap NDA. 03/16/26 https://t.co/KS84a3PWcp

$ABVX cash and equivalents of EUR 590M ($693M), with a cash runway into Q4'27

$GUTS Announces Call of Tranche A Warrants Tied to August 2025 Public Offering. Holders will have until December 30 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9M in potential gross proceeds https://t.co/Fd0nmtElL5

$JBIO $45M PIPE at $14/share

$IMNM Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors Trial met primary endpoint with varegacestat significantly improving PFS vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints,

$VNDA Submits BLA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

$KYTX Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel in Stiff Person Syndrome. Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single